Nykode Therapeutics AS
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of local… Read more
Nykode Therapeutics AS (VACBF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.056x
Based on the latest financial reports, Nykode Therapeutics AS (VACBF) has a cash flow conversion efficiency ratio of -0.056x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.17 Million) by net assets ($91.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nykode Therapeutics AS - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Nykode Therapeutics AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Nykode Therapeutics AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nykode Therapeutics AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Groundhog Inc.
TW:6906
|
0.028x |
|
Hancock & Gore Ltd
AU:HNG
|
0.013x |
|
Cosmax
KO:044820
|
0.045x |
|
SMO
BK:SMO
|
-0.220x |
|
Chenghe Acquisition II Co.
NYSE MKT:CHEB
|
-0.002x |
|
ABITARE IN S.P.A.
F:1BN
|
N/A |
|
Melcor Real Estate Investment Trust
TO:MR-UN
|
0.005x |
|
Daesung Hi-Tech Co. Ltd.
KQ:129920
|
0.020x |
Annual Cash Flow Conversion Efficiency for Nykode Therapeutics AS (2019–2025)
The table below shows the annual cash flow conversion efficiency of Nykode Therapeutics AS from 2019 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $91.54 Million | $-29.46 Million | -0.322x | +14.42% |
| 2024-12-31 | $136.21 Million | $-51.22 Million | -0.376x | +33.35% |
| 2023-12-31 | $171.26 Million | $-96.62 Million | -0.564x | -328.11% |
| 2022-12-31 | $157.02 Million | $-20.69 Million | -0.132x | -2314.19% |
| 2021-12-31 | $194.06 Million | $1.16 Million | 0.006x | -99.41% |
| 2020-12-31 | $178.85 Million | $180.27 Million | 1.008x | +392.48% |
| 2019-12-31 | $30.44 Million | $-10.49 Million | -0.345x | -- |